The application of CDK16 inhibitors in the treatment of triple-negative breast cancer

被引：0
|
作者：
Xiao, Haihua
Jiang, Huangyu
Feng, Kunxian
Yang, Mengli
Yang, Jinping
Jian, Chengfang
Tian, Yuan
Vasilevich, Natalya
Sun, Lichun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5345
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5345
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
    Li, Xiao
    Li, Jinpeng
    Xu, Liming
    Wei, Wei
    Cheng, Anyi
    Zhang, Lingxian
    Zhang, Mengna
    Wu, Gaosong
    Cai, Cheguo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [2] CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
    Xiao Li
    Jinpeng Li
    Liming Xu
    Wei Wei
    Anyi Cheng
    Lingxian Zhang
    Mengna Zhang
    Gaosong Wu
    Cheguo Cai
    Journal of Experimental & Clinical Cancer Research, 41
  • [3] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [4] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [5] The application of exosomes in the treatment of triple-negative breast cancer
    Weaver, John W. W.
    Zhang, Jinyu
    Rojas, Juan
    Musich, Phillip R. R.
    Yao, Zhiqiang
    Jiang, Yong
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [6] Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
    Wang, Runtian
    Xu, Kun
    Gao, Fangyan
    Huang, Jinyi
    Guan, Xiaoxiang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [7] CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Goel, Shom
    Tolaney, Sara M.
    LANCET ONCOLOGY, 2019, 20 (11): : 1479 - 1481
  • [8] Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
    Hu, Ye
    Gao, Jiyue
    Wang, Meiling
    Li, Man
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5223 - 5237
  • [9] Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
    Zhu, Xiuzhi
    Chen, Li
    Huang, Binhao
    Li, Xiaoguang
    Yang, Liu
    Hu, Xin
    Jiang, Yizhou
    Shao, Zhimin
    Wang, Zhonghua
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [10] Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
    Xiuzhi Zhu
    Li Chen
    Binhao Huang
    Xiaoguang Li
    Liu Yang
    Xin Hu
    Yizhou Jiang
    Zhimin Shao
    Zhonghua Wang
    Journal of Experimental & Clinical Cancer Research, 40
12345